GPR17 is an orphan G protein-coupled receptor that serves as a critical regulator of oligodendrocyte precursor cell (OPC) differentiation and myelination in the central nervous system 1. The receptor acts as a dual specificity receptor for uracil nucleotides and cysteinyl leukotrienes, signaling through Gi protein coupling and inhibition of adenylyl cyclase. GPR17 functions as a negative regulator of OPC maturation, with its abnormal upregulation blocking precursor cells at immature premyelinating stages and preventing effective remyelination 2. In disease contexts, GPR17 emerges as a promising therapeutic target for multiple sclerosis, with antagonists like HAMI3379 promoting oligodendrocyte differentiation in both rodent and human cells 3. The receptor also regulates metabolic processes, as intestinal GPR17 deficiency improves glucose tolerance by promoting GLP-1 secretion from enteroendocrine cells 4. Recent clinical developments include PTD802, the first GPR17 antagonist clinical candidate for MS therapy 5. Additionally, GPR17 has been implicated in rare genetic diseases, with associations identified in conditions including schizophrenia 6. The receptor's role in blocking remyelination makes it an attractive target for treating demyelinating diseases and stroke recovery 7.